MNKD Mannkind Corp

$MNKD Why $12 Changes Everything — But Doesn’t End the MNKD Thesis AeroLab Institutional Research | MNKD There is a scene in The Gambler that I find myself thinking about whenever I think about MannKind at $12. John Goodman’s character, Frank, is explaining what he believes someone should do once they’ve accumulated enough money. His advice is essentially this: Own your house. Have reliable transportation. Put enough money somewhere safe that nobody can take your independence away from you. Then comes the line that defines the entire speech: “A wise man’s life is based around fuck you.” Your boss becomes unreasonable? You can walk. Someone wants you to take a risk you don’t want to take? No. The market goes against you? You don’t have to sell. You have built yourself a fortress. The brilliance of the speech isn’t the profanity. It’s the idea behind it. Money eventually stops being about buying things and starts being about buying freedom. That’s what I think about when I think about MNKD at $12. Not Lamborghinis. Not private jets. Not calling the top. Optionality. For long-term MannKind shareholders, I think $12 could represent something similar. Not because $12 is necessarily where MNKD should ultimately be valued. In fact, if the company’s current growth engines execute, I believe $12 could eventually look more like an intermediate milestone than a destination. But $12 would change the equation. First, put $12 in perspective. Using approximately 322 million shares outstanding: $12 × 322 million = approximately $3.86 billion market capitalization. That sounds like a large number until you look at what MannKind is becoming. This is no longer the old single-product Afrezza story. MannKind now has multiple independent revenue engines. Afrezza The pediatric indication has opened an entirely new market while the adult franchise continues to develop. Q2 included only a limited period of pediatric contribution, yet Afrezza generated $17 million in net sales. And pediatric Afrezza isn’t simply another indication. It’s potentially an opportunity to introduce inhaled insulin much earlier in a patient’s lifetime. FUROSCIX FUROSCIX generated $22.2 million in Q2, up 43% sequentially, while units increased 49%. Now ReadyFlow changes both the usability and economics of the franchise. Management is guiding to $110–$120 million of FUROSCIX revenue in 2026 while expecting substantially greater contribution from the second half of the year. This is becoming a legitimate second commercial franchise. United Therapeutics Then there is United Therapeutics. Tyvaso DPI continues producing royalty and manufacturing economics for MannKind. And the relationship may eventually expand through ralinepag DPI. That’s particularly important because royalty revenue behaves differently from traditional pharmaceutical product revenue. MannKind doesn’t need to build another massive commercial organization to capture it. UTHR does the heavy lifting. MannKind participates in the economics. And United’s pulmonary hypertension and pulmonary fibrosis expansion strategy potentially gives that royalty stream a very long runway. MNKD-201 Then there is the asset that could eventually force investors to rethink the entire valuation. MNKD-201. The Phase 1b INFLO-1 results provided early clinical validation of inhaled nintedanib in actual IPF patients. Phase 2 is where we begin finding out whether MannKind has something much bigger. And this is the part I believe is crucial: MNKD-201 doesn’t require Afrezza to fail. It doesn’t require FUROSCIX to fail. It doesn’t require Tyvaso DPI royalties to disappear. These opportunities stack. That’s what makes the MannKind of the next several years fundamentally different from the MannKind many shareholders have owned for the last decade. So why does $12 matter? Because $12 would represent something the stock hasn’t provided long-term shareholders in years: Optionality. At $4, you have to wait. At $12, you get to choose. Take some money off the table. Pay off debt. Diversify. Fund retirement. Build a permanent cash reserve. Or don’t sell a single share. That’s the point. You’re no longer making the decision because you have to. You’re making it because you want to. That’s financial independence. And that’s why I wouldn’t automatically view $12 as an exit price. What gets us to $12 matters more than $12 itself. If MNKD simply traded at $12 tomorrow without the fundamentals improving, I’d look at $12 very differently. But imagine reaching $12 because the underlying business earned its way there. FUROSCIX moves beyond its current guidance. ReadyFlow accelerates adoption while improving the cost structure. Pediatric Afrezza gains traction. Adult Afrezza continues growing. Tyvaso DPI royalties expand. Ralinepag DPI moves toward commercialization. MNKD-201 advances successfully through Phase 2. And MannKind returns to sustained profitability as today’s investments begin producing operating leverage. Now ask yourself: If all of that is happening, why would $12 automatically be the end of the story? It wouldn’t. There are two very different ways MNKD can reach $12. Scenario One: Multiple Expansion The market simply decides today’s MannKind deserves a higher valuation. That’s good. But there’s another possibility. Scenario Two: Fundamental Expansion Revenue grows into the valuation while the pipeline simultaneously becomes more valuable. That’s much more powerful. Because in the second scenario, the denominator keeps moving. The company you valued at $12 isn’t the same company you valued at $4. Maybe revenue is considerably higher. Maybe margins are better. Maybe profitability is established. Maybe UTHR royalties have become a substantially larger recurring revenue stream. Maybe MNKD-201 has been clinically derisked. At that point, the question changes. For years we’ve asked: “How does MNKD get to $12?” Eventually we may need to ask: “What is MNKD worth after it gets there?” That’s the question I’m increasingly interested in. The Fortress And that brings me back to The Gambler. The lesson wasn’t to stop taking risks. It was to reach a position where you control which risks you take. There’s an enormous difference. For a long-term MNKD shareholder, $12 could provide that opportunity. Sell a little. Sell nothing. Diversify. Let the rest ride. Whatever you decide, the important thing is that it’s your decision. You aren’t trapped by the investment anymore. You’ve built the fortress. For me, that’s why $12 isn’t the finish line. It’s the point where a decade-long investment thesis could finally begin creating something even more valuable than another dollar on the share price: Freedom of choice. At $4, you have to wait. At $12, you get to choose. And maybe that’s the best way to describe what $12 could ultimately mean for long-term MNKD shareholders. Not goodbye. Fuck you money. ⸻ Disclosure: I am long MNKD. This article represents my personal opinions and research and is not investment advice. Investors should conduct their own due diligence and consider their individual financial circumstances and risk tolerance.

$MNKD Martine Rothblatt presentation at today's Wells Fargo Conference today was very positive favoring Tyvaso DPI and Ralinepag DPI, unlike what she did during United's 2Q 2026, Earnings Call attcking DPi. Today Martine had nothing but great things to say about MNKD and DPI. She referred to MNKD as being a great partner. She confirmed Tyvaso DPI is moving forward for IPF and PPF and the big news IMO was Martine saying Ralinepag DPI, is a better drug versus Tyvaso Treprostinil, more efficacious and only needs once a day inhalation that MNKD developed. She expects Ralinepag DPI will become the drug of choice for PAH, PH-ILD. IPF and PPF over Treprostinil products and United is prepared to support the large growth in Ralinepag DPI with a new Technosphre DPI manufacturing plant unveiling in Oct. then going to the FDA for approval. Ralinepag DPI is going to be a huge revenue driver for United and MNKD. Softmist inhaler got some mention but United Therapeutic is on board 100% with MNKD DPI

$MNKD furoscix switching delivery method is huge and a way bigger deal than inhalable insulin. It was crazy how little SCPH sold for with this in the pipeline.

$MNKD After listening to Martine today, It looks like Ralinepag DPI is the holy grail that will drive huge revenues to United Therapeutic and Mannkind. Ralinepag DPI will become the drug of choice as a standalone and combiantion therapy that will capture most of the marketshare for PAH, PH-ILD, IPF and PPF. That will include capturing and taking marketshare away from Treprositinil drugs like Tyvaso DPI and Yutrepria.

$MNKD Martine justtake over Mannkind make an offer nobody can ignore nor refuse please

$MNKD With it looking more and more like the short-term traders are just about cleaned up after locking in some nice profits (but leaving a lot on the table - ah, the opportunity costs associated with being a trader rather than an investor, eh? ;-) ) after scooping up shares back in March and April... and The Sour Grapes Bunch out in force again over the last few days reminding us how upset they are that Mike and his team are finding success despite taking the company in a different direction than those folks wanted him to take... things could get exciting if the market experiences its typical (but not guaranteed!) post-Labor Day rally next week... so stay tuned, eh? ;-) As always, here's to more gains in the years ahead! Cheers! #knowwhatyouown #factsmatter

$MNKD let’s get back to business everyone!! excited to hear the news this week. We’re definitely getting some adoption of this exciting technology

$MNKD nom nom nom... into another nice delivery at the close! Who doesn't love seeing such a bullish pattern developing over the past several weeks, eh? ;-) #iykyk

$MNKD Labor Day And For Diabetes Healthcare Professionals & Educators For endocrinologists, Certified Diabetes Care and Education Specialists (CDCES), and researchers, Labor Day is a moment to recognize the intense, emotionally demanding work required to support millions of patients. • The "Invisible Shift": Diabetes education isn't just about writing prescriptions. It involves teaching patients how to balance carbohydrates, navigate insurance for continuous glucose monitors (CGMs), and handle the mental burnout of a chronic condition. Happy Labor Day ~ The Vdex Team #HappyLaborDay2026 #BloodSugarControl #DiabeticAwareness #DiabetesCommunity #DiabeticLife

$MNKD Next week United Therapeutic is first up presenting at the Wells Fargo Conference on Tuesday Sept 8th and then they come back on Wednesday to present at the Cantor Conference Sept 9th and then it's Mannkind turn on Thursday Sept 10th when they also present at the Cantor Conference. Hoping for a big week with United Therapeutic talking about Tyvaso DPI and Ralinepag DPI with a possible outside chance they will have something new to say about their relationship with Mannkind and Mannkind talking about Afrezza Pediatric and Furoscix Readyflow launches, Nintedanib DPI Phase II with possible news about FDA decision to allow U.S. locations in the study and additional business development updates. Today Mannkind stock price closed out the week @ $4.06 and hoping it finally cracks above $5 closing out next week in a very positive manner. Good luck to all longs Mannkind Long Kevinmik

$MNKD 60% more volume at this time of the day today than pretty much every other day this week... and great price/volume action (albeit quite a bit lighter than it will end up being once the stock really gets moving) heading into a 3-day weekend! Looking forward to seeing whether the end of day pattern repeats itself again today... stay tuned, eh?

$MNKD feel like this stock won’t take off till I’m 90 and on my deathbed. Guess I’ll hold for the grandkids lol

$MNKD So much better muting that mornon. It’s obvious it’s his job, why would anyone ever sit here all day and post like that - ridiculous static. Anyways thank goodness for the mute button.

$MNKD 😲 🚨 ALL analyst's price targets for MNKD are higher than where it currently trades. MUCH higher! Buy some shares, for the good of all Mannkind! Roar Kitty!🐱 🤑 $SPY 💲 $QQQ 💲 $GME 🤑

$MNKD At least it looks like MannKind’s absence from the Wells Fargo conference wasn’t due to any change in Wells Fargo’s view on the company.

$MNKD Does anyone feel like this week something really big will come from UTHR? Hopefully we see a press release tomorrow by United Therapeutics!!! Super bullish!!!!!!!!

$MNKD both amgn and nvs got decimated today. Amgen lost ~22 billion in market cap and NVS lost ~45 billion. One would think they could make some of that up by buying out MNKD for $5 billion. 🙏

$MNKD judging by the known Bashers replying to my post... that tells me that I must be right over the target. I know already

$MNKD Looks like Martine has learned how to talk to the street.. very nice to see. A breath of fresh air.

$MNKD Bank of New York Mellon purchased 898,463 MannKind shares worth approximately $3.83 million, giving it a 0.29% stake TUTES LOVE MNKD